Baird analyst Brian Skorney raised the firm’s price target on Gilead (GILD) to $100 from $95 and keeps a Neutral rating on the shares. The firm noted its Q4 results revealed another beat for Biktarvy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $110 from $105 at Piper Sandler
- Gilead price target raised to $120 from $105 at Wells Fargo
- Gilead Sciences: Balancing Strong HIV Franchise Performance with Cautious Outlook
- Gilead Sciences Reports Strong 2024 Financial Performance
- Gilead Sciences: Strong Financial Performance and Promising Future Prospects Justify Buy Rating